Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (27): 4960-4963.doi: 10.3969/j.issn.1673-8225.2010.27.005

Previous Articles     Next Articles

Effect of human bone marrow mesenchymal stem cells on T cell activation in patients with systemic lupus erythematosus

Dong Yi1, Liu Lei2, Xia Rui-xiang1, Zeng Qing-shu1, Li Qing-sheng1   

  1. 1Department of Hematology, 2Department of Rheumatology, the Third Affiliated Hospital of Bengbu Medical College, Suzhou  234011, Anhui Province, China
  • Online:2010-07-02 Published:2010-07-02
  • Contact: Li Qing-sheng, Doctor, Professor, Chief physician, Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China
  • About author:Dong Yi, Master, Associate chief physician, Department of Hematology, the Third Affiliated Hospital of Bengbu Medical College, Suzhou 234011, Anhui Province, China dongyixx@126.com
  • Supported by:

    A Grant from the Education Department of Anhui Province, No. 2006kj417B*

PDF

539

Abstract:

BACKGROUND: Bone marrow mesenchymal stem cells (BMMSCs) have immunological effects and can treat autoimmune disease.

OBJECTIVE: To explore the effect of human BMMSCs on T cell activation in patients with systemic lupus erythematosus (SLE) in vitro.

METHODS: BMMSCs were cultured and the 3rd passage cells were digested by trypsin. The concentration of cells was identified by flow cytometry. And MMSCs were divided into 1×108/L and 1×107/L group. Totally 10 mL peripheral blood lymphocytes (PBL) were obtained from 27 cases with SLE and incubated into BMMSCs with concentration of 1×109/L, 100 µL per well. Expression rates of CD3+ T cells CD25 (IL-2R) and CD38 were calculated by flow cytometry.

RESULTS AND CONCLUSION: Compared with the control group, the expression of CD25 and CD38 were obviously suppressed in the 1×108/L group (P < 0.01). But there was no significant change in the 1×107/L group. The results demonstrated that BMMSCs inhibit T cell activation in patients with SLE in a dose-dependent manner.

CLC Number: